Archives: Resources

Kristen Hsu, ARC’s Executive Director of Research, presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research.

The webinar concluded with a Q&A session.

Original Presentation Date:
April 15, 2025.

Download the Slides →

0:00 — Welcome

4:00 — Introduction

6:40 — What is a Clinical Trial?

7:52 — Clinical Trial Phases

13:00 — What makes a study a good fit for me?

16:09 — AL Amyloidosis Clinical Trial Overview

25:00 — AL Amyloidosis Trials Recruiting in 2025

25:54 — LINKER-AL2 (Relapsed/refractory AL amyloidosis)

30:04 — ENTENTAMIG (Relapsed/refractory AL amyloidosis)

33:17 — NEXICART-2 (Relapsed/refractory AL amyloidosis)

35:53 — AFFIRM-AL (Newly diagnosed AL amyloidosis)

38:58 — Upcoming Milestones for AL Therapies in 2025

43:00 — Future Development for AL Therapies

45:35 — Other Recruiting and Planned Clinical Trials

49:30 — How to Find Clinical Trials

52:48 — Q&A Session

53:37 — How do measurements of “free light chains” relate to disease progression?

56:10 — Which study is appropriate for patients who have already had an autologous stem cell transplant?

57:13 — Could CAR-T cell therapy eventually replace stem cell transplants?

58:08 — What is the timeline between a study concluding and treatments becoming available?

1:00:29 — What is the impact of current federal policy changes on amyloidosis research?

1:03:46 — Conclusion

Contact ARC:

Call +1 (617) 467-5170

Email ARC at support@arci.org